-
1.发明授权Methods of measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor and uses thereof 有权测量von Willebrand因子的ADAMTS13介导的体内裂解的方法及其用途公开(公告)号：US08415114B2
公开(公告)日：2013-04-09
申请号：US12630509
申请日：2009-12-03
申请人： Katalin Varadi , Hanspeter Rottensteiner , Peter Turecek , Hans-Peter Schwarz , Jutta Schreiner
发明人： Katalin Varadi , Hanspeter Rottensteiner , Peter Turecek , Hans-Peter Schwarz , Jutta Schreiner
IPC分类号： C12Q1/56
CPC分类号： G01N33/86 , C12Q1/37 , C12Q1/56 , G01N33/573 , G01N2333/755 , G01N2333/96486 , G01N2800/224 , G01N2800/52
摘要： The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
摘要翻译： 本发明一般涉及测量切割的血管性血友病因子（VWF）片段的方法。 更具体地，本发明涉及测量具有血小板反应蛋白1型基序，成员13（ADAMTS13）在体内切割VWF的解联蛋白和金属蛋白酶的能力的方法。 本发明还涉及使用表现出与人相似的ADAMTS13活性的各种动物模型的方法。 本发明还涉及测量哺乳动物，特别是人和人血浆中rVWF的切割产物的方法。
-
2.发明申请METHODS OF MEASURING ADAMTS13-MEDIATED IN VIVO CLEAVAGE OF VON WILLEBRAND FACTOR AND USES THEREOF 有权方法测量ADAMTS13-介导VIV WILLEBRAND因子的血液透析及其用途公开(公告)号：US20100143957A1
公开(公告)日：2010-06-10
申请号：US12630509
申请日：2009-12-03
申请人： Katalin Varadi , Hanspeter Rottensteiner , Peter Turecek , Hans-Peter Schwarz , Jutta Schreiner
发明人： Katalin Varadi , Hanspeter Rottensteiner , Peter Turecek , Hans-Peter Schwarz , Jutta Schreiner
IPC分类号： C12Q1/34
CPC分类号： G01N33/86 , C12Q1/37 , C12Q1/56 , G01N33/573 , G01N2333/755 , G01N2333/96486 , G01N2800/224 , G01N2800/52
摘要： The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
摘要翻译： 本发明一般涉及测量切割的血管性血友病因子（VWF）片段的方法。 更具体地，本发明涉及测量具有血小板反应蛋白1型基序，成员13（ADAMTS13）在体内切割VWF的解联蛋白和金属蛋白酶的能力的方法。 本发明还涉及使用表现出与人相似的ADAMTS13活性的各种动物模型的方法。 本发明还涉及测量哺乳动物，特别是人和人血浆中rVWF的切割产物的方法。
-
3.发明授权Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-pegylation) 有权使用可释放的PEG试剂（体外去PEG化）测定前药PEG蛋白缀合物中活性成分的方法公开(公告)号：US09274122B2
公开(公告)日：2016-03-01
申请号：US12582497
申请日：2009-10-20
申请人： Katalin Varadi , Gerald Schrenk , Hanspeter Rottensteiner , Peter Turecek , Alfred Weber , Heinz Anderle , Sean M. Culbertson , Zhihao Fang , Harold Zappe , Ping Zhang , Mary J. Bossard
发明人： Katalin Varadi , Gerald Schrenk , Hanspeter Rottensteiner , Peter Turecek , Alfred Weber , Heinz Anderle , Sean M. Culbertson , Zhihao Fang , Harold Zappe , Ping Zhang , Mary J. Bossard
CPC分类号： G01N33/68 , G01N33/542 , G01N33/582 , G01N33/86 , G01N2333/76
摘要： The invention relates to the development of in vitro assay systems that force the release of a water-soluble polymer, such as polyethylene glycol (PEG) and polysialic acid (PSA), from proteins modified with a reversibly-linked water-soluble polymer. The invention includes methods for analyzing the release of the water-soluble polymer and measuring regained protein activity. The invention further includes methods appropriate for the quality control of proteins modified with releasable water-soluble polymers, including polymers like PEG and PSA.
摘要翻译： 本发明涉及从用可逆连接的水溶性聚合物改性的蛋白质强制释放水溶性聚合物如聚乙二醇（PEG）和聚唾液酸（PSA）的体外测定系统的开发。 本发明包括用于分析水溶性聚合物的释放并测量重新获得的蛋白质活性的方法。 本发明还包括适用于用可释放水溶性聚合物（包括聚合物如PEG和PSA）改性的蛋白质的质量控制的方法。
-
4.发明申请METHODS FOR DETERMINING ACTIVE INGREDIENTS IN PRO-DRUG PEG PROTEIN CONJUGATES WITH RELEASABLE PEG REAGENTS (IN VITRO DE-PEGYLATION) 有权使用可释放的PEG试剂（在体外去PEG化）中测定丙型肝素PEG蛋白质结合物中活性成分的方法公开(公告)号：US20100112607A1
公开(公告)日：2010-05-06
申请号：US12582497
申请日：2009-10-20
申请人： Katalin Varadi , Gerald Schrenk , Hanspeter Rottensteiner , Peter Turecek , Alfred Weber , Heinz Anderle , Sean M. Culbertson , Zhihao Fang , Harold Zappe , Ping Zhang , Mary J. Bossard
发明人： Katalin Varadi , Gerald Schrenk , Hanspeter Rottensteiner , Peter Turecek , Alfred Weber , Heinz Anderle , Sean M. Culbertson , Zhihao Fang , Harold Zappe , Ping Zhang , Mary J. Bossard
CPC分类号： G01N33/68 , G01N33/542 , G01N33/582 , G01N33/86 , G01N2333/76
摘要： The invention relates to the development of in vitro assay systems that force the release of a water-soluble polymer, such as polyethylene glycol (PEG) and polysialic acid (PSA), from proteins modified with a reversibly-linked water-soluble polymer. The invention includes methods for analyzing the release of the water-soluble polymer and measuring regained protein activity. The invention further includes methods appropriate for the quality control of proteins modified with releasable water-soluble polymers, including polymers like PEG and PSA.
摘要翻译： 本发明涉及从用可逆连接的水溶性聚合物改性的蛋白质强制释放水溶性聚合物如聚乙二醇（PEG）和聚唾液酸（PSA）的体外测定系统的开发。 本发明包括用于分析水溶性聚合物的释放并测量重新获得的蛋白质活性的方法。 本发明还包括适用于用可释放水溶性聚合物（包括聚合物如PEG和PSA）改性的蛋白质的质量控制的方法。
-
公开(公告)号：US20060003921A1
公开(公告)日：2006-01-05
申请号：US11218406
申请日：2005-09-02
IPC分类号： A61K38/37
CPC分类号： A61K38/37
摘要： Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWF propeptide as well as a method for producing such a preparation.
摘要翻译： 描述了一种用于治疗凝血障碍的药物制剂，其包含有效量的vWF前肽以及制备这种制剂的方法。
-
6.发明申请KIT FOR MEASURING THE THROMBIN GENERATION IN A SAMPLE OF A SAMPLE OF A PATIENT'S BLOOD OR PLASMA 有权用于测量患者血液或血浆样本中样品的血小板生成的试剂盒公开(公告)号：US20130052672A1
公开(公告)日：2013-02-28
申请号：US13539154
申请日：2012-06-29
IPC分类号： G01N21/64
CPC分类号： A61K31/66 , C12Q1/56 , G01N33/86 , G01N2333/745
摘要： The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and CaCl2. The invention also provides processes for preparing the reagents for the kit. The kit can be used in a method for measuring the thrombin generation in a sample, wherein it is possible to detect changes in thrombin generation kinetics, for example after administration of inhibitor bypassing agents to a patient who has developed inhibitors to an exogenous clotting factor such as Factor VIII.
摘要翻译： 本发明提供了一种用于测量患者血液或血浆样品或凝血因子样品中的凝血酶产生的试剂盒。 该试剂盒含有冻干组织因子/磷脂复合物和含有凝血酶底物和CaCl 2的冻干混合物。 本发明还提供了用于制备试剂盒的试剂的方法。 该试剂盒可以用于测量样品中凝血酶产生的方法，其中可以检测凝血酶产生动力学的变化，例如在将抑制剂旁路剂施用于已经开发出外源凝血因子的抑制剂的患者之后 作为因子VIII。
-
7.发明申请Kit for measuring the thrombin generation in a sample of a patient's blood or plasma 审中-公开用于测量患者血液或血浆样品中凝血酶产生的试剂盒公开(公告)号：US20050221414A1
公开(公告)日：2005-10-06
申请号：US10816099
申请日：2004-03-31
CPC分类号： A61K31/66 , C12Q1/56 , G01N33/86 , G01N2333/745
摘要： The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and CaCl2. The invention also provides processes for preparing the reagents for the kit. The kit can be used in a method for measuring the thrombin generation in a sample, wherein it is possible to detect changes in thrombin generation kinetics, for example after administration of inhibitor bypassing agents to a patient who has developed inhibitors to an exogenous clotting factor such as Factor VIII.
摘要翻译： 本发明提供了一种用于测量患者血液或血浆样品或凝血因子样品中的凝血酶产生的试剂盒。 试剂盒含有冻干组织因子/磷脂复合物和含有凝血酶底物和CaCl 2 2的冻干混合物。 本发明还提供了用于制备试剂盒的试剂的方法。 该试剂盒可以用于测量样品中凝血酶产生的方法，其中可以检测凝血酶产生动力学的变化，例如在将抑制剂旁路剂施用于已经开发出外源凝血因子的抑制剂的患者之后 作为因子VIII。
-
公开(公告)号：US07005502B1
公开(公告)日：2006-02-28
申请号：US09424498
申请日：1998-05-26
申请人： Hans-Peter Schwarz , Katalin Varadi , Peter Turecek , Hendrik Coenraad Hemker , Suzette Lucette Beguin
发明人： Hans-Peter Schwarz , Katalin Varadi , Peter Turecek , Hendrik Coenraad Hemker , Suzette Lucette Beguin
CPC分类号： A61K38/37
摘要： Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWf propeptide as well as a method for producing such a prepartion.
摘要翻译： 描述了用于治疗凝血障碍的药物制剂，其包含有效量的vWF前肽以及制备这种制剂的方法。
-
9.发明授权Kit for measuring the thrombin generation in a sample of a patient's blood or plasma 有权用于测量患者血液或血浆样品中凝血酶产生的试剂盒公开(公告)号：US08735086B2
公开(公告)日：2014-05-27
申请号：US13539154
申请日：2012-06-29
IPC分类号： C12Q1/56
CPC分类号： A61K31/66 , C12Q1/56 , G01N33/86 , G01N2333/745
摘要： The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and CaCl2. The invention also provides processes for preparing the reagents for the kit. The kit can be used in a method for measuring the thrombin generation in a sample, wherein it is possible to detect changes in thrombin generation kinetics, for example after administration of inhibitor bypassing agents to a patient who has developed inhibitors to an exogenous clotting factor such as Factor VIII.
摘要翻译： 本发明提供了一种用于测量患者血液或血浆样品或凝血因子样品中的凝血酶产生的试剂盒。 该试剂盒含有冻干组织因子/磷脂复合物和含有凝血酶底物和CaCl 2的冻干混合物。 本发明还提供了用于制备试剂盒的试剂的方法。 该试剂盒可以用于测量样品中凝血酶产生的方法，其中可以检测凝血酶产生动力学的变化，例如在将抑制剂旁路剂施用于已经开发出外源凝血因子的抑制剂的患者之后 作为因子VIII。
-
10.发明授权Methods of treating blood coagulation disorders using a pharmaceutical preparation comprising vWF propeptide 有权使用包含vWF前肽的药物制剂治疗血液凝固障碍的方法公开(公告)号：US07557188B2
公开(公告)日：2009-07-07
申请号：US11218406
申请日：2005-09-02
申请人： Hans-Peter Schwarz , Katalin Varadi , Peter Turecek , Hendrik Coenraad Hemker , Suzette Lucette Beguin
发明人： Hans-Peter Schwarz , Katalin Varadi , Peter Turecek , Hendrik Coenraad Hemker , Suzette Lucette Beguin
CPC分类号： A61K38/37
摘要： Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWF propeptide as well as a method for producing such a preparation.
摘要翻译： 描述了一种用于治疗凝血障碍的药物制剂，其包含有效量的vWF前肽以及制备这种制剂的方法。
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.028 秒)
